CJC-1295 is a long-acting growth-hormone-releasing hormone analogue. Small studies in healthy adults showed sustained rises in GH and IGF-1, but clinical development stopped and there are no long-term safety or performance data.
Key points
- Healthy-volunteer studies demonstrated prolonged GH and IGF-1 elevation after single injections.
- No trial measured muscle, fat or performance outcomes as primary endpoints.
- Development was discontinued; long-term safety was never established.
- Products sold online under this name have not been independently verified; label identity and concentration cannot be assumed.
What the literature shows
Teichman and colleagues reported dose-dependent increases in GH and IGF-1 lasting days after a single CJC-1295 dose in healthy adults.
Ionescu and Frohman showed that pulsatile GH secretion was preserved during CJC-1295 exposure, an endocrinology finding rather than a physique outcome.
What remains unknown
- Effects of repeated exposure over months on glucose control and growth-sensitive tissues.
- Equivalence between 'with DAC' and 'without DAC' retail products and studied material.
Safety and monitoring implications
- Sustained IGF-1 elevation raises theoretical concerns for glucose tolerance and tissue growth.
- Injection-site reactions and flushing were reported in trials.
Cited literature
- 1.Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. Find on PubMed
- 2.Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedCommunity discussion of this compound is widespread, but no independently verified reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying CJC-1295 (with DAC) in Australia: what to check first
APEDRA does not sell CJC-1295 (with DAC) or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.